Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · melanoma-umap@29

SRR10900548

—

7fccc794-2b6f-5dd7-9881-57795e9d300f

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • ALLOGRAFT_REJECTION+0.300
  • COMPLEMENT+0.300
  • E2F_TARGETS+0.300
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.300
  • INFLAMMATORY_RESPONSE+0.300
  • INTERFERON_ALPHA_RESPONSE+0.300
  • INTERFERON_GAMMA_RESPONSE+0.300
  • TNFA_SIGNALING_VIA_NFKB+0.300
  • UV_RESPONSE_UP+0.300
  • WNT_BETA_CATENIN_SIGNALING+0.300

Top 10 suppressed

  • OXIDATIVE_PHOSPHORYLATION-0.200
  • PROTEIN_SECRETION-0.200
  • UV_RESPONSE_DN-0.200
  • ANDROGEN_RESPONSE-0.100
  • FATTY_ACID_METABOLISM-0.100
  • HEDGEHOG_SIGNALING-0.100
  • MYC_TARGETS_V1-0.100
  • NOTCH_SIGNALING-0.100
  • ADIPOGENESIS+0.000
  • APICAL_SURFACE+0.000

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

9 twins match this tumor's tissue · 1 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
120050099.TNBC
breast-umap@18
—D0.848
2BS_D8N31T39
brain-umap@2
low-grade glioma—0.844
3TCGA-BH-A0B3-01A-11R-A056-07
breast-umap@18
—E0.841
4DRR168610
bladder-landscape@3
——0.807
5R317
bladder-landscape@3
——0.803
6AUR-AFUI-TTP1-A-1-0-R-A743-41
breast-umap@18
—C0.800
7MNG653
mng-umap@100
——0.797
8TCGA-A7-A6VY-01A-12R-A33J-07
breast-umap@18
—E0.796
920060013.TNBC
breast-umap@18
—E0.795
1025B5E54F-5858-454C-9B23-440A82450912
brain-umap@2
——0.792

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 32 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
ALLOGRAFT_REJECTION0.300Idelalisib— uncovered
COMPLEMENT0.300Inavolisib— uncovered
E2F_TARGETS0.300Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.300Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.300Idelalisib— uncovered
INTERFERON_ALPHA_RESPONSE0.300Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.300Idelalisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.300Inavolisib— uncovered
UV_RESPONSE_UP0.300Idelalisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.300Inavolisib— uncovered
ANGIOGENESIS0.200Remibrutinib— uncovered
APOPTOSIS0.200Idelalisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.200Remibrutinib— uncovered
COAGULATION0.200Binimetinib— uncovered
G2M_CHECKPOINT0.200Inavolisib— uncovered
IL2_STAT5_SIGNALING0.200Idelalisib— uncovered
MYC_TARGETS_V20.200Idelalisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.200Inavolisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.200Idelalisib— uncovered
APICAL_JUNCTION0.100Inavolisib— uncovered